Physician profile
Robert A Williams
NPI 1730109778
$54,358.80
in general payments reported to CMS, 2019-2025
38 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,160 · 2020: $2,192 · 2021: $41K · 2022: $4,047 · 2023: $1,675 · 2024: $1,568 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43,504.49 | 2019-2023 | Andexxa |
| Abbott Laboratories | $2,037.14 | 2019-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $1,649.65 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,322.56 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $1,022.10 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $928.05 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Pfizer INC. | $713.11 | 2019-2025 | |
| Amgen INC. | $520.59 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $359.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.00 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $310.90 | 2019-2025 | Lifevest |
| Inspire Medical Systems, INC. | $172.46 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $134.38 | 2019-2025 | Evkeeza |
| Medtronic Vascular, INC. | $130.42 | 2019 | |
| Daiichi Sankyo INC. | $126.85 | 2020-2025 | Injectafer |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.